Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award
April 30 2008 - 9:39AM
PR Newswire (US)
Causal Network Modeling Provides Powerful Approach to Modeling
Complex Biological Systems for Type 2 Diabetes CAMBRIDGE, Mass.,
April 30 /PRNewswire/ -- Genstruct Inc., a systems biology company
focused on identifying molecular mechanisms, networks and
biomarkers to better understand large scale biology, today
announced that its joint collaboration with Sirtris
Pharmaceuticals, Inc. (NASDAQ:SIRT), a biopharmaceutical company
focused on discovering and developing small molecule drugs to treat
diseases of aging, has won Bio-IT World magazine's 2008 Best
Practices Award in the Drug Discovery & Development category.
The project was focused on discovering mechanisms of action (MOA)
for Type 2 diabetes. The two companies collaborated to further
characterize the molecular MOA of Sirt1 activating compounds. In
blinded analysis, Genstruct's causal network modeling (CNM)
approach concluded that the strongest hypothesis for the results
seen in the Sirtris Type 2 diabetes study was caloric restriction
(CR) -- showing that Sirtris' SIRT1 activators are mimicking the
effects of CR. These results were confirmed by in vitro and in vivo
experimentations. "We are honored that our collaboration with
Sirtris has been recognized for our unique approach to modeling
complex biological systems," said Dr. Keith O. Elliston, president
and CEO at Genstruct. "Using our CNM platform, we were able to help
develop a deep understanding of the SIRT1 pathway and allowed
Sirtris to efficiently analyze a vast quantity of data. Sirtris has
been a valued research partner for our firm." Genstruct's unique
CNM platform for systems biology has been designed to integrate and
model data from multiple large-scale measurement modalities and has
been successfully applied to biomarker discovery, MOA definition
and drug safety assessment. Genstruct and Sirtris received this
award on April 29 at the 2008 Best Practices VIP Gala Awards Dinner
at the World Trade Center in Boston, Mass. Fifty-five entries were
submitted and were judged by a panel of experts based on the
nominees' novel and innovative uses of technology to improve the
efficiency and economics of R&D, drug discovery and clinical
research and trials. About Genstruct Founded in 2002, Genstruct is
a biotechnology company focused on elucidating the complexity of
biology for the development of successful therapeutics. By modeling
the components within the whole biological system, Genstruct
delivers a deep molecular understanding of diseases and drug
action, as well as mechanistic biomarkers to accelerate drug
discovery and development programs. Genstruct engages in internal
discovery and external development partnerships with top tier
pharmaceutical companies, which apply systems biology in the areas
of oncology, metabolic disorders, cardiovascular diseases and
inflammation. The privately held company is based in Cambridge,
Mass. For more information, please visit http://www.genstruct.com/.
Genstruct and the Genstruct logo are registered trademarks and
Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are
trademarks of Genstruct, Inc. All other trademarks or registered
trademarks are properties of their respective owners. Contacts:
Karen Higgins A & E Communications for Genstruct (610) 831-5723
DATASOURCE: Genstruct Inc. CONTACT: Karen Higgins of A & E
Communications for Genstruct, +1-610-831-5723, Web site:
http://www.genstruct.com/
Copyright
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals (MM) News Articles